NVCT
NASDAQNuvectis Pharma Inc.
News · 26 weeks31+250%
2026-03-012026-08-23
Mix2490d
- SEC Filings10(42%)
- Insider7(29%)
- Offering3(13%)
- Other2(8%)
- Earnings1(4%)
- Analyst1(4%)
Latest news
25 items- ANALYSTCantor Fitzgerald initiated coverage on Nuvectis PharmaCantor Fitzgerald initiated coverage of Nuvectis Pharma with a rating of Overweight
- SECSEC Form S-3 filed by Nuvectis Pharma Inc.S-3 - Nuvectis Pharma, Inc. (0001875558) (Filer)
- SECNuvectis Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)
- INSIDERVice President, Finance Carson Michael J. was granted 30,000 shares, increasing direct ownership by 15% to 230,118 units (SEC Form 4)4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
- SECSEC Form 10-Q filed by Nuvectis Pharma Inc.10-Q - Nuvectis Pharma, Inc. (0001875558) (Filer)
- SECNuvectis Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)
- PRNuvectis Pharma Reports Second Quarter 2026 Financial Results and Business HighlightsCompleted in-licensing of ex-China rights to two potentially best-in-class compounds (NXP100 and NXP200) from Haisco Pharmaceutical Group ("Haisco"), transforming the company into a late-stage clinical development organization.The Company’s lead drug candidate, Ciprocopan (NXP100), a Complement Factor B inhibitor for once-daily, oral administration, was approved in China in July 2026 for the treatment of patients with PNH Previously Untreated with Complement Inhibitors.Completed follow-on offering in July 2026, raising $115M in gross proceeds. Transaction anchored by leading healthcare dedicated investors and extends cash runway into 1H 2029. FORT LEE, N.J., Aug. 04, 2026 (GLOBE NEWSWIRE)
- PRCorrection: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement InhibitorsFirst global approval of a once-daily, orally administered, Complement Factor B inhibitorApproval based on robust efficacy and safety data from Haisco's broad completed clinical development program in PNHCiprocopan application for marketing approval in China for the treatment of patients with PNH previously treated with anti-C5 therapies is currently under reviewCiprocopan has the potential to become an effective therapy in multiple complement-mediated diseases and provide a convenience advantage as a once-daily oral treatment option for patients requiring continuous life-long treatment Fort Lee, NJ, July 23, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the
- PRCiprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement InhibitorsFirst global approval of a once-daily, orally administered, Complement Factor B inhibitorApproval based on robust efficacy and safety data from Haisco's broad completed clinical development program in PNHCiprocopan application for marketing approval in China for the treatment of patients with PNH previously treated with anti-C5 therapies is currently under reviewCiprocopan has the potential to become an effective therapy in multiple complement-mediated diseases and provide a convenience advantage as a once-daily oral treatment option for patients requiring continuous life-long treatment Fort Lee, NJ, July 23, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the
- INSIDERLarge owner Mosseri Marlio Charles bought $916,000 worth of shares (50,000 units at $18.32) (SEC Form 4)4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
- INSIDERChairman & CEO Bentsur Ron bought $250,000 worth of shares (12,500 units at $20.00), increasing direct ownership by 0.34% to 3,688,424 units (SEC Form 4)4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
- SECNuvectis Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)
- SECSEC Form 424B5 filed by Nuvectis Pharma Inc.424B5 - Nuvectis Pharma, Inc. (0001875558) (Filer)
- PRNuvectis Pharma Announces Pricing of $100 Million Public Offering of Common StockFORT LEE, N.J., June 29, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT), a clinical stage biopharmaceutical company focused on the development of innovative therapies for the treatment of immune complement-related conditions and oncology, today announced the pricing of its previously announced underwritten public offering of 5,000,000 shares of its common stock at a price of $20.00 per share, with expected gross proceeds to Nuvectis of $100 million. Nuvectis has also granted the underwriters a 30-day option to purchase up to 750,000 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to clos
- SECSEC Form 424B5 filed by Nuvectis Pharma Inc.424B5 - Nuvectis Pharma, Inc. (0001875558) (Filer)
- SECNuvectis Pharma Inc. filed SEC Form 8-K: Other Events8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)
- PRNuvectis Pharma Announces Proposed Public Offering of Common StockFORT LEE, NJ, June 29, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT), a clinical stage biopharmaceutical company focused on the development of innovative therapies for the treatment of immune complement-related conditions and oncology, today announced that it has commenced an underwritten public offering of its common stock. All of the shares to be sold in the offering will be offered by Nuvectis. In addition, Nuvectis intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when
- SECNuvectis Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)
- PRNuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage CompoundsThe transaction transforms Nuvectis into a late-stage clinical development company by expanding its pipeline into complement-mediated diseases with the in-licensing of a Complement Factor B inhibitor (CFBi [NXP100]) and also enhances the oncology product pipeline with the in-licensing of a paradox breaker BRAF inhibitor (BRAFi [NXP200]) for the treatment of BRAF-mutated malignancies.NXP100 (HSK39297): A once-daily, oral CFBi in late-stage development for the treatment of complement-mediated diseases. Current development status in China includes:Two Marketing Authorization Applications (MAAs) are under review for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH); The applications see
- INSIDERDirector Hoberman Kenneth was granted 35,000 shares, increasing direct ownership by 26% to 168,140 units (SEC Form 4)4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
- INSIDERDirector Oliviero James F Iii was granted 35,000 shares, increasing direct ownership by 40% to 122,828 units (SEC Form 4)4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
- INSIDERDirector Sanchez Juan was granted 35,000 shares, increasing direct ownership by 45% to 113,380 units (SEC Form 4)4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
- INSIDERDirector Kaplan Matthew L. was granted 35,000 shares, increasing direct ownership by 28% to 159,760 units (SEC Form 4)4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
- SECNuvectis Pharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)
- PRNuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQFort Lee, NJ, May 14, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that management will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 19, 2026 in New York. Conference Details: Date: Tuesday, May 19, 2026Company Presentation: 9:00 – 9:30AM EDTPresenter: Ron Bentsur, Chairman and Chief Executive Officer of NuvectisWebcast Link: hereLocation: New York, NY A webcast of the presentation will be avai
NVCT FAQ
7 questionsWhat does Nuvectis Pharma Inc. do?
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.Where does NVCT stock trade?
Nuvectis Pharma Inc. (NVCT) is listed on NASDAQ.What sector and industry is NVCT in?
Nuvectis Pharma Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Nuvectis Pharma Inc. go public?
Nuvectis Pharma Inc. (NVCT) completed its IPO in 2022.What are analysts saying about NVCT?
Nuvectis Pharma Inc. has had 5 recent analyst actions on file. The most recent action was from Cantor Fitzgerald: Overweight on 2026-08-24. Recent price targets range from $1400.00 to $2100.00.What companies are similar to NVCT?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare NVCT side-by-side with any of them on Quantisnow.How can I track NVCT on Quantisnow?
Quantisnow aggregates Nuvectis Pharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NVCT to receive live email and push alerts on every new disclosure.